種々の条件下におけるLymphokine Activated Killer (LAK) 細胞の誘導, およびその殺細胞効果に及ぼす抗癌剤の影響

Invitroにおける検討

抄録

To establish the combination of chemotherapy with adoptive immunotherapy (AIT), using lymphokine activated killer cells (LAICa) nd/or interleukin-2 (IL-2) a, u thor examined the following:
1) Pretreatment with anticancer agents for peripheral blood mononuclear cells (PBMC) and its effect on LAIC cell cytotoxicity and cell yield.
2) The addition of anticancer agents in the induction phase to LAIC cell and its effect on LAIC cell cytotoxicity and cell yield.
3) Pretreatment with anticancer agents to induced LAICc ell and its effect on LAK cell cytotoxicity and cell yield.
4) The cytotoxicity of LAIC cell against tumor cells treated with anticancer agents.
Our experiment has shown that when we take peripheral blood mononuclear cells (PBMC) to induce LAK cells, there is no influence on its LAICc ell yield or its cytotoxicity after being harvested as LAICc ells, even if there is a maximum concentration of anticancer agents, but in the case of the LAICc ell induction phase VDS, CDDP, ADM and MMC have a significant effect on LAIC cell yield and on cytotoxicity of LAK cell after being arvested as LAIC cells.
And it has also been shown that, if there is a maximum concentration of anticancer agents, it has an effect on the induced LAK cell cytotoxicity and on the LAICc ell yield after being recultured with IL-2.
On the other hand, LAIC cell cytotoxicity makes no difference to tumor cells whether they are treated or not with anticancer agents.
These results suggest that we can take peripheral blood mononuclear cells to induce LAIC cells unrelated to the administration of anticancer agents, and that if we use a combination of chemotherapy with adoptive immunotherapy (IL-2 administration and/or LAK cell adoptation), we should start with the administration of anticancer agents and then administer IL-2 and/or transfer LAK cells after the concentration of anticancer agents decreased under 1/10 of maximum concentration in the blood level of our conventionally clinical use.